ArticleScientific reports2026
Finerenone attenuates myocardial injury and enhances vascular repair via regulation of autophagy, apoptosis, and angiogenesis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, has demonstrated significant efficacy in the management of myocardial infarction (MI). However, its direct cytoprotective effects on cardiomyocytes and vascular endothelial cells remain unclear. This study was performed to evaluate the cardioprotective and vasoprotective effects of finerenone following MI and to elucidate its underlying mechanisms. An in vitro oxygen-glucose deprivation (OGD) model was utilized to mimic ischemic conditions. H9C2 rat cardiomyoblasts and human umbilical vein endothelial cells were employed to assess the protective effects of finerenone. For in vivo assessment, a murine model of MI was established and treated with oral finerenone for 28 consecutive days. Cardioprotective outcomes were evaluated through electrocardiography, echocardiography, serum biochemical markers, histopathological analyses, and protein expression profiling. Finerenone significantly improved the viability of cardiomyocytes and endothelial cells subjected to OGD, reduced autophagosome accumulation by enhancing autophagosome degradation, inhibited apoptosis, and promoted endothelial cell migration and tube formation capacity. In vivo, finerenone improved cardiac function parameters, reduced serum levels of myocardial enzyme profiles and brain natriuretic peptides, decreased myocardial infarct size, enhanced left ventricular function, and alleviated myocardial inflammation, fibrosis and apoptosis. Mechanistically, finerenone downregulated the expression of ATG5 and apoptosis-related molecules in myocardial tissue, while enhancing the expression of Ang and VEGF involved in angiogenesis. Finerenone confers significant cardioprotection by inhibiting autophagy, apoptosis, and enhancing angiogenesis in both cardiomyocytes and vascular endothelial cells. These findings provide experimental evidence for the clinical utility of finerenone for secondary prevention after MI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.